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Abstract
Aims: Estimate the prevalence of cannabis dependence and its contribution to the global burden of disease.
Methods: Systematic reviews of epidemiological data on cannabis dependence (1990-2008) were conducted in line
with PRISMA and meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Culling and data
extraction followed protocols, with cross-checking and consistency checks. DisMod-MR, the latest version of generic
disease modelling system, redesigned as a Bayesian meta-regression tool, imputed prevalence by age, year and sex
for 187 countries and 21 regions. The disability weight associated with cannabis dependence was estimated through
population surveys and multiplied by prevalence data to calculate the years of life lived with disability (YLDs) and
disability-adjusted life years (DALYs). YLDs and DALYs attributed to regular cannabis use as a risk factor for
schizophrenia were also estimated.
Results: There were an estimated 13.1 million cannabis dependent people globally in 2010 (point prevalence0.19%
(95% uncertainty: 0.17-0.21%)). Prevalence peaked between 20-24 yrs, was higher in males (0.23% (0.2-0.27%))
than females (0.14% (0.12-0.16%)) and in high income regions. Cannabis dependence accounted for 2 million
DALYs globally (0.08%; 0.05-0.12%) in 2010; a 22% increase in crude DALYs since 1990 largely due to population
growth. Countries with statistically higher age-standardised DALY rates included the United States, Canada,
Australia, New Zealand and Western European countries such as the United Kingdom; those with lower DALY rates
were from Sub-Saharan Africa-West and Latin America. Regular cannabis use as a risk factor for schizophrenia
accounted for an estimated 7,000 DALYs globally.
Conclusion: Cannabis dependence is a disorder primarily experienced by young adults, especially in higher income
countries. It has not been shown to increase mortality as opioid and other forms of illicit drug dependence do. Our
estimates suggest that cannabis use as a risk factor for schizophrenia is not a major contributor to population-level
disease burden.
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Introduction
Cannabis is a generic term for preparations (e.g. marijuana,
hashish and hash oil) derived from the cannabis sativa plant[1].
The cannabis plant contains more than 60 unique
cannabinoids. The one that is primarily responsible for the
psychoactive effects that cannabis users typically seek is
delta-9-tetrahydrocannabinol or THC[2-4], which is found in a
resin on the flowering tops and upper leaves of the female
plant. Most of the other cannabinoids are either inactive or only
weakly active, although they may interact with THC[3,5] (2,4).
THC acts upon a specific cannabinoid receptor (CB1) in the
brain[6].
Cannabis is widely used in developed and developing
countries[7,8]. Global patterns of cannabis use have been
estimated by the United Nations Office on Drugs and Crime
(UNODC)[9] but there has not been a systematic review of
global, regional and country-level patterns of cannabis
dependence and disease burden. This information is critical to
inform policy and programming to prevent and treat this
disorder.
The global burden of disease (GBD) framework was initiated
by the World Bank report of 1993 [10] and uses information on
mortality and disability associated with a given disease to
estimate the years of life lost due to premature mortality (YLLs)
and the years lived with disability (YLDs). YLLs and YLDs can
be summed into disability adjusted life years (DALYs), an
overall summary measure of disease burden.
Previous GBD studies (GBD 1990 and its subsequent
updates) significantly enhanced the global awareness of the
burden of mental and substance use disorders[11-13] but did
not include cannabis dependence. In 1990 the drug use
disorder estimate was defined as ‘dysfunctional and harmful
drug use’[11] and in 2002 ‘opioid dependence and harmful use
and cocaine dependence’ were included as one group[12].
In 2002, the GBD “comparative risk assessment” (CRA)
exercise[14] estimated the proportion of disease burden
attributable to alcohol, tobacco, and illicit drug use[14].
Cannabis use was not included as a risk factor for any disease
due to concerns about the quality of the evidence[15]. In the
intervening years, there has been a steady increase in the
quantity and quality of research on cannabis use and psychosis
(or schizophrenia)[16-18]. Overall, these studies indicate that
chance is an unlikely explanation of their association[16-18].
Recent reviews of prospective general population studies of
associations between cannabis use and later psychosis[17,18]
concluded that although control for confounding reduced the
size of the association, there was an increased risk of
psychotic outcomes in individuals who used cannabis, with the
greatest risk among those who used cannabis most frequently.
It is useful to distinguish two primary ways in which cannabis
use could be a “cause” of psychosis[19]. The strongest form of
causal link is that heavy cannabis use causes a psychosis that
would not otherwise have occurred. A second hypothesis is
that cannabis use is a contributory cause: it might precipitate
psychosis in vulnerable individuals - that it is one factor among
many (including genetic predisposition and other unknown
causes) that act together to cause psychotic disorders.
The evidence suggests that it is more likely than not that
cannabis use precipitates schizophrenia in vulnerable
persons[20-24]. This is consistent with other lines of evidence
suggesting that there is a complex constellation of factors
leading to the development of psychosis (the stress-diathesis
model of schizophrenia) and with studies suggesting that gene-
environment interactions may provide some explanation of the
association [20]. It is also consistent with conflicting evidence
to date on whether changes in cannabis use have been
associated with changes in the incidence of psychotic disorders
in the general population[21-23]. There is also some evidence
that cannabis use is associated with increased likelihood of
relapse to psychosis among those who have developed a
psychotic disorder [25], although the quality of control for
confounding in these studies is poor [25]. In some studies
cannabis use has also been associated with a younger age of
onset of psychosis [26], although control for confounding
variables in these has also been poor.
Aims
GBD 2010 updated the burden estimation methodology and
estimated the burden of 291 diseases and 67 risk factors, by
age, sex, 187 countries, and 21 world regions, for 1990, 2005
and 2010. It included both the direct burden attributable to
cannabis dependence and the additional burden arising from
cannabis dependence as a risk factor for other health
outcomes. As part of the GBD 2010 study, we conducted
systematic reviews of the literature to capture all the available
data since 1990 on the prevalence and consequences of
cannabis dependence. Other methodological improvements
included: the use of a Bayesian meta-regression approach to
model the epidemiological data and propagate uncertainty
around final burden estimates; the quantification of disability for
a more comprehensive list of health states using survey data
from a more representative sample; and adjusting burden
estimates for the effects of comorbid disorders[27,28].
This paper builds on our systematic reviews of the
epidemiology of cannabis use and dependence[29-32], and the
relationship between cannabis use and
schizophrenia[24,30,33], and expands on previous analyses of
the contribution of illicit drug use to the global burden of
disease[27,28,34-36]. We expand considerably in this paper on
what has been previously reported by conducting the first
assessment of the global burden of cannabis dependence. We
1) outline the methodology used to estimate burden for this
disorder specifically; 2) assemble data on the incidence and
prevalence of cannabis use and dependence into a
comprehensive disease model which adjusts for known
sources of variability between studies; 3) investigate trends in
the burden of cannabis dependence; and finally 4) investigate
the model used in GBD 2010 to estimate the global burden of
disease attributable to cannabis dependence as a risk factor for
schizophrenia.
Global Disease Burden of Cannabis Dependence
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Methods
Case definition
The case definition of cannabis dependence was based on
the Diagnostic and statistical manual of mental disorders
(DSM)[37] and International classification of diseases (ICD)[38]
diagnostic criteria for cannabis dependence (DSM:304.30;
ICD:F12.2).
Systematic reviews
Systematic searches were conducted for studies published
since 1990 to identify data sources for the prevalence,
incidence, remission and all-cause excess mortality attributable
to cannabis use and dependence. Full detail of these searches
has been published elsewhere[30-32,39,40].The search
strategy adhered to PRISMA guidelines[41] and used the
methodology recommended by the Meta-analysis of
Observational Studies in Epidemiology (MOOSE) group[42].
All extraction and quality assurance procedures were as
recommended by the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE)
guidelines[43]. Studies were excluded if they did not contain
primary data (e.g. review articles) or they contained data
collected before 1990. We extracted estimates of annual
incidence, current (including past-month) prevalence and
period (past year, past-month) prevalence. Remission from
cannabis dependence was defined as no longer fulfilling the
diagnostic criteria for the disorder. For remission studies, we
only included prospective studies that reported on a follow-up
of at least three years [30].
An additional literature search identified any evidence of drug
use within other regions. Evidence of any use was based on
reports of derived estimates of use[44], sample estimates,
drug-related treatments, drug seizures, drug-related arrests, or
other qualitative information related to the use of illicit drugs.
Sources of any use information include United Nations Office of
Drugs and Crime reports, government reports, surveys, news
reports and journal articles. We located evidence of cannabis
use or dependence for almost all of the world’s population aged
15-64 years (201 countries/territories; 99.8% of the world’s
population aged 15-64 years). There were estimates of the
prevalence of cannabis use in 108 countries. We identified 13
studies (60 data points) from 4 GBD regions that reported on
the prevalence of cannabis dependence. We found an
additional 7 studies (57 data points) from 5 GBD regions
reporting on weekly cannabis use and 80 studies (1313 data
points) from 17 GBD regions reporting on past year cannabis
use. We found only three general population cohort studies that
reported on the incidence of cannabis use or dependence. We
found no epidemiological evidence of elevated mortality risk
attributable to cannabis dependence (for full details
see[31,39]). The decision was therefore made not to assume
elevated mortality for cannabis dependence. Details of the
number and location of estimates are presented in Figure S1
and Table S1.
DisMod-MR modelling
We pooled these epidemiological estimates in a disease
model that was judged to have face validity by the GBD 2010
Expert Group and additional experts in cannabis use
epidemiology, in terms of age and sex patterns for the disease,
differences in incidence or prevalence between regions, and
changes in these parameters over time. For these estimates
we used DisMod-MR[28,45], the latest application of an
incidence-prevalence-mortality (IPM) mathematical model[46],
re-designed as a Bayesian meta-regression tool for GBD 2010.
The IPM model was implemented as a negative-binomial rate
model to ensure internal consistency between separate
estimates of prevalence, incidence, remission and excess-
mortality. DisMod-MR was also used to predict epidemiological
estimates for regions with no available data using country
random intercepts, and prevalence estimates from elsewhere
in the region and respective super-regional groupings (for
details of GBD regions see Table S2). We preferred high
quality, direct epidemiological estimates. In their absence, we
used predicted estimates rather than exclude regions with no
epidemiological data from GBD 2010 estimates[28,45].
There were two steps to use prevalence estimates of
cannabis use to model cannabis dependence. Step one used
DisMod-MR to model cannabis use and step two modelled
cannabis dependence. Region-, sex- and year-specific
cannabis use prevalence DisMod-MR output for the 20 to 44
age groups from step 1 were inserted into the cannabis
dependence dataset. Cannabis use estimates were restricted
to these age groups so as not to inflate the ratio of use to
dependence and thereby make it difficult for DisMod-MR to
derive a plausible fit to the cannabis dependence estimates.
We used a ‘cannabis use’ study-level covariate to adjust
estimates of cannabis use downwards towards its
corresponding level if the studies produced survey estimates of
cannabis dependence (see Text S1 for an example of
adjustment impacts). Values for incidence were set to zero
before age 13 and after age 60 because the disorder is rare in
children under 13 years and very rarely occurs for the first time
in persons older than 60 years[47]. Incidence was derived
using prevalence and remission and assuming no elevated
mortality[31]. For examples of outputs see Figure S2.
Disability weights
To estimate disability weights, a lay person description of
cannabis dependence was formulated by the Expert Group as
one of 222 lay descriptions that reflected the 291 diseases and
their sequelae in GBD 2010. Full details of this process have
been reported in Text S1 and elsewhere [36,48]. The survey
was completed by community samples in five countries
(Bangladesh, Indonesia, Peru, the United Republic of Tanzania
and the United States of America) and by respondents to an
open-access internet survey. In both, a pair-wise comparison
method, asking respondents to nominate the healthier of a pair
of health states, was used to arrive at an estimate of the level
of disability for each GBD health state.
In keeping with the way in which GBD 2010 dealt with
severity, survey data were used to adjust each disability weight
for the severity of disorder. Full details of the process have
Global Disease Burden of Cannabis Dependence
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been reported in Text S1 and elsewhere [27,28]. After adjusting
the DW for an estimated 51% (47%-54%) of cases who had no
disability and accounting for comorbidity, the average disability
weight for cannabis dependence was 0.162 (0.109 to 0.224).
Comorbidity adjustments
In order to correct YLDs for comorbidity, microsimulation
methods were used to generate hypothetical populations by
age, sex, year and country. Details are in Text S1and reported
in full elsewhere in [27,28].
Calculation of YLDs, YLLs and DALYs
GBD 2010 estimated ‘prevalent’ YLDs by multiplying
prevalence estimates from DisMod-MR by the disability weight.
DisMod-MR prevalence and burden estimates were stratified
by sex, age, country and 21 GBD regions (see http://
www.globalburden.com.au/docs/Regions.pdf and Table S2 for
country groupings), and for the years 1990, 2005, and 2010.
We explored time trends in burden by breaking down the
change in DALYs between 1990 and 2010 into changes that
were attributable to: population growth, population ageing and
sex structure, and changes in the epidemiology of cannabis
dependence. As we found no evidence of excess deaths[31]
(and therefore YLLs) directly attributable to cannabis
dependence, the YLDs comprised all of DALY estimates[28].
Comparative risk assessment (CRA): Cannabis use as
a risk factor for schizophrenia
We reviewed existing literature on cannabis use as a risk
factor for other health outcomes[24,31], as part of the CRA
component of the study[34]. This review concluded that there
was sufficient evidence to consider cannabis use as a risk
factor for schizophrenia. We considered several ways in which
cannabis and schizophrenia may be causally linked: 1) a model
that assumed greater disorder severity among those using
cannabis regularly who have already developed the disorder;
2) a model that assumed the association reflects earlier onset
of schizophrenia among those who would have developed it
anyway; 3) a model that assumed reduced remission from
schizophrenia once it developed; and 4) a model that assumed
an increased incidence of schizophrenia.
After consideration, approaches 3 and 4 were excluded from
core GBD analyses because of the lack of data to
systematically quantify the relationship across different studies
while accounting for confounding variables. Approaches 1 and
2 were deemed more plausible on the basis of the literature[24]
and so were included simultaneously in the modelling.
Two systematic literature reviews were conducted on the
global epidemiology of regular (weekly) cannabis use[29,32]
and schizophrenia[49,50] respectively. Details are provided
below. More information on the methodology is provided
elsewhere [34].
Data on regular (weekly or more frequent) cannabis use
in the past year
We defined the exposure as weekly or more frequent
cannabis use in the previous year because regular use is most
consistently associated with this outcome. We found seven
studies reporting prevalence of weekly or more frequent
cannabis use in the past year, from 15 countries and five GBD
world regions; and 80 studies on the prevalence of past-year
cannabis use, from 82 countries and 17 GBD world
regions[29,32].
The epidemiological data available for regular cannabis use
were modelled using DisMod-MR. Estimates of prevalence
were derived separately for 21 world regions, males and
females, 5 year age groups. We assumed zero incidence and
prevalence of regular cannabis use before age 13 as this led to
the most plausible fit to the data. A study-level covariate was
used to adjust estimates of past year cannabis use towards the
estimates of weekly cannabis use. Prevalence from past year
use were 3.79 (3.48-4.13) times higher than estimates of
weekly cannabis use and were adjusted downwards
accordingly.
Modelling earlier age of onset of schizophrenia
The effect of cannabis use on schizophrenia was modelled
via two pathways: the first by bringing forward the average age
of onset in persons with no cannabis use, and the second by
increasing the severity of schizophrenia. To account for the
effects of the first pathway, we calculated the counterfactual
average duration of schizophrenia across all ages under a
scenario of no cannabis use, and compared this to the
currently observed duration. To determine the counterfactual
average duration of schizophrenia, we brought incident cases
of schizophrenia who used cannabis forward by 2.70 (95% CIs:
1.96-3.43) years using results of a systematic meta-analysis
[51].
We used the estimates of cannabis use by age (in single
years), sex, country and year described above, assuming that
the prevalence of regular cannabis use was the same among
individuals with and without schizophrenia. Estimates of the
number of incident cases and the corresponding duration of
schizophrenia by age, sex, country and year were based on the
DisMod-MR model for schizophrenia. The value of one minus
the ratio of the counterfactual to the observed duration is an
estimate of the population attributable fraction of schizophrenia
due to the effect of regular cannabis use on age of onset.
Modelling increased severity of schizophrenia
To calculate the burden associated with the second pathway
of shifting severity, we used the odds ratio (OR) from Foti et
al[52] of psychotic symptoms of 1.64 (95% CIs: 1.12-2.34) in
people with schizophrenia who regularly use cannabis
compared to those who do not. We converted the ORs to their
RR equivalents based on the prevalence of exposure to regular
cannabis use and the percent of time with psychosis (as
opposed to residual state). The percent of time spent in acute
psychosis was 63% (38%-82%) based on a meta-analysis of 6
studies covering 5 GBD world regions[49].
We used the estimates of cannabis use by age (in single
years), sex, country and year described above and assumed
that the prevalence of regular cannabis use was the same
among individuals with and without schizophrenia. Estimates of
the number of incident cases and the corresponding duration of
Global Disease Burden of Cannabis Dependence
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e76635
schizophrenia by age, sex, country and year were based on the
DisMod-MR model. We used the linear relationship between
the estimated change in disability weight (based on the
proportion of time spent in a psychotic state) and the
prevalence of regular cannabis use to calculate the percent of
schizophrenia disability attributable to regular cannabis use.
Further detail on the modelling is found in Text S2.
Where we report comparisons of prevalence and DALYs by
country or region we use age-standardised values using direct
standardisation to the global standard population proposed by
WHO in 2001 (http://www.who.int/healthinfo/paper31.pdf).
Results
Prevalence of cannabis dependence
There were an estimated 11 million cases of cannabis
dependence globally in 1990 and 13 million cases in 2010.
These translated into pooled point prevalence estimates of
0.20% (95% uncertainty interval: 0.17-0.22%) in 1990 and
0.19% (0.17-0.21%) in 2010. These prevalence estimates were
pooled across all regions and standardised by the 2010 global
population age and sex. Figure 1 plots the point prevalence in
2010 by region, age and sex.
Prevalence was higher in males (0.23% (0.2-0.27%)) than
females (0.14% (0.12-0.16%)) producing a male: female sex
ratio of 1.8 (1.7-1.9). Prevalence peaked in the 20-24 years
age group at between 0.4% (0.3-0.6%) and 3.4% (2.8-4.2%) in
males across regions, and between 0.2% (0.16-0.4%) and
1.9% (1.5-2.4%) in females. It decreased steadily with age
thereafter.
The regional variation in prevalence is summarised in Figure
2 and Table 1 (data on estimated prevalence and prevalence
cases by region in 1990 is also reported in Table S3).
Prevalence in high income regions was much higher than that
in low to middle income regions and the global average.
Cannabis dependence in Australasia (the region with the
highest prevalence, 0.68%) was about 8 times higher than
prevalence in Sub-Saharan Africa, West (the region with the
lowest prevalence, 0.08%).Table S4 also contains estimates of
country-level prevalence of cannabis dependence. The wide
and overlapping confidence intervals around some country and
regional prevalence estimates indicate that not all variations in
prevalence were statistically significant.
Burden of cannabis dependence
Cannabis dependence accounted for 0.07% (0.05-0.1%) of
global DALYs in 1990 and 0.08% (0.05—0.12%) in 2010.
Although there was no change in the estimated contribution of
cannabis dependence to global DALYs, there was an increase
in crude DALYs across this period that was attributable to a
25% increase in population, a 6% decrease due to population
ageing and a 1% increase in the prevalence rate of cannabis
dependence. The net effect was a 22% increase in DALYs
attributable to cannabis dependence between 1990 and 2010.
The remainder of the results focus on 2010 data. There were
2 million DALYs attributable to cannabis dependence in 2010,
all YLDs. This accounted for 12.5% of YLDs attributable to illicit
drug use and 0.27% (0.17-0.4%) of global all-cause YLDs. The
majority of cannabis dependence YLDs occurred between 20
and 24 years (33.5% of cannabis dependence YLDs). In males
this age group accounted for 64.3% of cannabis dependence
YLDs. Figure 3 presents YLDs by age and sex.
Table 2 presents the regional estimates of DALYs
attributable to cannabis dependence; and Figure 4 presents
age standardised DALY rates by country. There was
Figure 1.  Estimated prevalence (proportion) of cannabis dependence by age, sex and region, 2010.  
doi: 10.1371/journal.pone.0076635.g001
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Figure 2.  Pooled regional prevalence of cannabis dependence, 2010.  Note. Prevalence estimates were standardised by
population age and sex; AP-HI: Asia Pacific, High Income, As-C: Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia
Southeast, Aus: Australasia, Caribb: Caribbean, Eur-C: Europe Central, Eur-E: Europe Eastern, Eur-W: Europe Western, LA-An:
Latin America, Andean, LA-C: Latin America, Central, LA-Sth: Latin America, Southern, LA-Trop: Latin America, Tropical, Nafr-ME:
North Africa/Middle East, Nam-HI: North America, High Income, Oc: Oceania, SSA-C: Sub-Saharan Africa, Central, SSA-E: Sub-
Saharan Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: Sub-Saharan Africa, West.
doi: 10.1371/journal.pone.0076635.g002
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substantial variation in DALYs between regions (table 2) and
between countries (Figure 4a) but most of this variation
occurred within wide and often overlapping bounds of
uncertainty (Figure 4b). Table S4 further details estimated
Table 1. Estimated prevalence and number of cases of cannabis dependence in 2010, by sex and GBD region.
 Females Males Total
 N % 95%CI N % 95%CI N % 95%CI
Asia Pacific, High Income 147000 0.19 (0.15-0.26) 238000 0.26 (0.18-0.36) 385000 0.17 (0.09-0.28)
Asia Central 71000 0.14 (0.08-0.24) 125000 0.24 (0.18-0.33) 197000 0.28 (0.18-0.41)
Asia East 925000 0.15 (0.11-0.20) 1430000 0.26 (0.22-0.31) 2355000 0.22 (0.17-0.29)
Asia South 1001000 0.28 (0.18-0.42) 1601000 0.35 (0.32-0.39) 2602000 0.15 (0.13-0.18)
Asia South East 365000 0.23 (0.12-0.39) 610000 0.35 (0.22-0.54) 975000 0.15 (0.11-0.19)
Australasia 55000 0.20 (0.12-0.31) 98000 0.30 (0.25-0.36) 153000 0.68 (0.60-0.78)
Caribbean 26000 0.21 (0.13-0.35) 44000 0.15 (0.12-0.19) 69000 0.16 (0.12-0.21)
Europe Central 92000 0.24 (0.18-0.33) 155000 0.22 (0.20-0.25) 247000 0.23 (0.18-0.29)
Europe Eastern 160000 0.26 (0.22-0.31) 272000 0.28 (0.17-0.44) 432000 0.22 (0.15-0.33)
Europe Western 422000 0.26 (0.18-0.36) 710000 0.46 (0.41-0.53) 1132000 0.34 (0.28-0.41)
Latin America, Andean 23000 0.35 (0.32-0.39) 39000 0.27 (0.17-0.44) 62000 0.11 (0.08-0.15)
Latin America, Central 79000 0.35 (0.22-0.54) 142000 0.24 (0.17-0.35) 221000 0.09 (0.07-0.13)
Latin America, Southern 63000 0.30 (0.25-0.36) 105000 0.29 (0.22-0.37) 168000 0.28 (0.19-0.43)
Latin America, Tropical 107000 0.15 (0.12-0.19) 179000 0.15 (0.09-0.23) 287000 0.14 (0.08-0.23)
North Africa/Middle East 276000 0.22 (0.20-0.25) 447000 0.15 (0.11-0.20) 723000 0.14 (0.12-0.18)
North America, High Income 654000 0.28 (0.17-0.44) 1084000 0.14 (0.08-0.24) 1737000 0.60 (0.53-0.68)
Oceania 8000 0.46 (0.41-0.53) 13000 0.15 (0.11-0.20) 21000 0.20 (0.13-0.31)
Sub-Saharan Africa Central 56000 0.27 (0.17-0.44) 95000 0.19 (0.15-0.26) 151000 0.16 (0.11-0.23)
Sub-Saharan Africa East 215000 0.24 (0.17-0.35) 374000 0.28 (0.18-0.42) 589000 0.16 (0.13-0.20)
Sub-Saharan Africa South 56000 0.29 (0.22-0.37) 92000 0.23 (0.12-0.39) 148000 0.18 (0.12-0.28)
Sub-Saharan Africa West 104000 0.15 (0.09-0.23) 171000 0.20 (0.12-0.31) 275000 0.08 (0.06-0.11)
Global 4906000 0.15 (0.11-0.20) 8023000 0.21 (0.13-0.35) 13,073,000 0.19% (0.17-0.21)
doi: 10.1371/journal.pone.0076635.t001
Figure 3.  Global cannabis dependence DALYs (all YLDs) by age and sex, in thousands, 2010.  
doi: 10.1371/journal.pone.0076635.g003
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country-level DALYs. As for estimated prevalence, there was
considerable uncertainty around estimated rates for some
countries and regions. The countries with statistically higher
DALY rates than the global average were all from North
America, high income, Australasia, and Europe Western
regions. The countries with lower DALY rates than the global
average were from Sub-Saharan Africa-West and Latin
America Central and Andean.
Figure 5 compares the burden of cannabis dependence to
other substance use disorders in GBD 2010. Cannabis
dependence was the only substance for which there were no
attributable deaths and hence zero YLLs. Globally, it accounted
for more DALYs than cocaine dependence, but fewer than the
other drug use disorders.
In high income regions such as Australasia, North America,
high income and Europe Western where we had better quality
epidemiological data available, the DALY rate (per 100,000) of
cannabis dependence surpassed that attributable to
amphetamine dependence (93.2 (61.7-134.2) vs. 58.5
(31.2-98.1) in Australasia; 43.03(27.0-62.3) vs. 34.5 (19.6-55.2)
in Europe Western; and 81.5 (53.6-116.6) vs. 33.4 (18.4-52.8)
in North America, high income).
Additional burden attributable to cannabis use as a risk
factor for schizophrenia
Regular cannabis use as a risk factor for schizophrenia
accounted for 7,000 DALYs (3,000-13,000) or 0.04%
(0.03-0.06%) of schizophrenia DALYs globally (Table 3).
Overall, North America, high income was the region with
highest number of attributable DALYs (2,000 DALYs). Males
were responsible for over twice as many attributable
schizophrenia DALYs (5,000 DALYs; 2,000-10,000) than
females (2,000; 1,000-4,000); and attributable DALYs peaked
between 25 and 30 years and decreased thereafter. When the
additional burden attributable to cannabis use as a risk factor
for schizophrenia was added to that of cannabis dependence,
cannabis use still accounted for 0.08% of global DALYs in
2010.
Discussion
To our knowledge this is the first study to estimate global,
regional, and country-level prevalence of cannabis
dependence, and to estimate its contribution to the global
burden of disease. An estimated 13 million people were
cannabis dependent in 2010, an age and sex-standardised
Table 2. Estimated DALYs for cannabis, by sex and GBD region, 2010.
 Females Males Persons
 N
Rates per
100,000 95%CI N
Rates Per
100,000 95%CI N
Rates Per
100,000 95%CI
 
Asia Pacific,
High Income 22000 24.4 (11.8-46.2) 39000 45.1 (21.5-82.5) 62000 34.5 (19.2-57.2)
 Asia Central 11000 27.7 (15.7-43.8) 20000 50.2 (29.2-81.0) 31000 38.7 (24.3-59.2)
 Asia East 135000 20.1 (7.9-45.2) 247000 34.1 (14.3-71.0) 382000 27.3 (13.4-50.5)
 Asia South 145000 18.6 (11.4-28.4) 270000 32.6 (19.7-48.7) 415000 25.8 (16.2-37.5)
Asia South East 56000 18.3 (10.4-29.8) 97000 32.0 (18.2-51.2) 153000 25.1 (15.8-37.7)
Australasia 8000 64.2 (41.5-93.7) 16000 122.5 (79.0-179.6) 24000 93.2 (61.7-134.2)
Caribbean 4000 18.1 (10.2-29.4) 7000 31.4 (17.6-49.5) 11000 24.7 (14.8-36.8)
Europe Central 14000 22.8 (13.6-35.8) 25000 43.9 (26.1-70.9) 39000 33.0 (20.5-50.1)
Europe Eastern 25000 22.9 (11.0-42.2) 43000 45.0 (22.3-78.6) 68000 33.1 (18.5-55.7)
Europe Western 64000 30.0 (18.4-44.6) 115000 56.5 (34.4-85.8) 179000 43.0 (27.0-62.3)
Latin America, Andean 4000 13.4 (6.3-23.0) 6000 23.0 (11.9-41.0) 10000 18.2 (10.2-29.8)
Latin America, Central 13000 11.2 (6.0-19.1) 22000 19.5 (10.5-32.7) 35000 15.3 (9.1-23.7)
Latin America, Southern 10000 31.0 (15.0-59.4) 17000 57.7 (28.6-106.7) 26000 44.1 (24.9-75.9)
Latin America, Tropical 17000 16.5 (6.5-34.5) 29000 29.4 (11.8-59.9) 46000 22.9 (11.4-41.0
North Africa/Middle East 40000 18.4 (11.4-28.6) 75000 33.0 (19.9-50.7) 115000 25.9 (16.2-37.7)
North America, High
Income 98000 57.1 (37.0-82.1) 178000 106.4 (66.6-156.6) 276000 81.5 (53.6-116.6)
Oceania 1000 24.4 (11.1-47.0) 2000 41.4 (20.3-81.9) 3000 33.1 (17.4-57.6)
Sub-Saharan Africa
Central 9000 17.7 (8.3-32.7) 14000 30.1 (14.5-57.0) 23000 23.9 (12.8-39.7)
Sub-Saharan Africa East 34000 18.8 (11.1-30.0) 58000 33.0 (19.9-51.7) 92000 25.9 (16.5-38.5)
Sub-Saharan Africa
South 8000 23.6 (11.4-43.5) 15000 42.3 (20.9-78.8) 23000 32.8 (18.0-56.4)
Sub-Saharan Africa West 16000 9.6 (5.3-15.8) 27000 16.0 (9.2-27.0) 43000 12.8 (8.0-20.4)
Global 734000 21.5 (14.1-31.4) 1323000 38.1 (24.4-55.4) 2057000 29.9 (19.5-43.1)
doi: 10.1371/journal.pone.0076635.t002
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Figure 4.  Country-level DALYs per 100,000 population for cannabis dependence, age-standardised, for 2010.  Note. Low:
shows countries with statistically lower DALY rates than global mean; Middle: Shows countries with DALY rates that are not
statistically different to global mean; High: Shows countries with statistically higher DALY rates than global mean.
doi: 10.1371/journal.pone.0076635.g004
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prevalence of 0.2% (0.17-0.22%). Prevalence was not
estimated to have changed significantly from 1990, although
increased population size produced an increase in the number
of cases of cannabis dependence over the period. Levels of
cannabis dependence were significantly higher in a number of
high income countries including Australia, New Zealand, the
United States, Canada, and a number of Western European
countries include the United Kingdom. Cannabis dependence
caused 2 million DALYs in 2010. DALY rates also varied
considerably geographically, with the highest rates again in
North America high income, Australasia and Western Europe.
There is clearly scope to reduce the burden associated with
cannabis dependence. The estimates presented in this paper
are potentially useful for service planning at global, regional
and country levels. Although cannabis use was estimated to be
a smaller contributor to disease burden than alcohol or opioids,
nonetheless some 2 million years lived with disability were
attributed to the drug. Behavioural interventions are effective in
the treatment of cannabis dependence[53,54], with cognitive
behavioural therapy and contingency management showing the
greatest promise. Public health campaigns may also be
necessary to advise young people of the risks of developing
Figure 5.  The proportion of DALYs due to cannabis dependence relative to other substance use disorders in GBD
2010.  Note. Alcohol use disorders included alcohol dependence and foetal alcohol syndrome; Other drugs: Burden attributable to
illicit drug types other than cannabis, opioid, amphetamine and cocaine dependence were estimated under residual categories in
GBD 2010.
doi: 10.1371/journal.pone.0076635.g005
Table 3. Estimated DALYs attributable to regular cannabis use as a risk factor for schizophrenia1, 2010.
 Persons Males Females
 Lower CI Mean Upper CI Lower CI Mean Upper CI Lower CI Mean Upper CI
Attributable YLLs - - - - - - - - -
Attributable YLDs 3,000 7,000 13,000 2,000 5,000 10,000 1,000 2,000 4,000
Attributable DALYs 3,000 7,000 13,000 2,000 5,000 10,000 1,000 2,000 4,000
Note. 1 Modelled with two effects; an earlier onset of schizophrenia among people using cannabis regularly; and increased time spent in the acute state of schizophrenia.
doi: 10.1371/journal.pone.0076635.t003
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dependence on cannabis because this risk may be
underappreciated by many users.
Based on the best available evidence, and models making
reasonable assumptions, we found that only 0.04% of the
DALYs attributed to schizophrenia were linked to regular
(weekly or more frequent) cannabis use. Although
epidemiological studies make a consistent case that early
and/or heavy cannabis use is linked to a significantly increased
risk of schizophrenia[24], the modest increase in risk and the
low prevalence of schizophrenia mean that regular cannabis
use accounts for only a very small proportion of the disability
associated with schizophrenia. From a population health
perspective, this raises doubt about the likely impact of
preventing cannabis use on the incidence or prevalence of
schizophrenia until further evidence finds that there is a causal
relationship between regular cannabis use and the onset of
new cases of psychotic illness [55].
Limitations
We have made estimates based on the best available
epidemiological data and used sophisticated modelling to
incorporate a range of sources of uncertainty about the
parameters used in our models. However, our reviews
identified clear gaps in existing epidemiological data on
cannabis dependence. A significant amount of research is
needed to document even the most basic epidemiological
parameters for cannabis dependence in most countries. Until
such work is done, considerable uncertainty will remain around
the exact size of global burden of disease that is attributable to
cannabis and other illicit drugs. This is particularly the case for
low income countries, where there is typically limited
information on use occurring, even less on levels of use, and
usually no data on prevalence of dependence. There is a clear
imperative to better assess levels of dependent drug use in
these countries whose populations may be experiencing higher
levels of burden than were estimated here.
Further, a range of potential health outcomes of cannabis
use were not included in our estimates. We considered
including suicide, cancer and accidental injuries but the
evidence for a causal relationship for these outcomes was
considered to be too weak to generate defensible global
estimates[31].
We also note that we assumed that levels of cannabis use
among people with schizophrenia were the same as the
general population. This was a conservative assumption. There
are data from clinical studies that very high levels of cannabis
use are found among patients with schizophrenia[56].
However, a systematic review found that available data on the
extent of this elevation were limited[56] to high income
countries. It is also useful to be mindful of the impact of this
assumption on the magnitude of the burden we are
considering. This particular aspect is only relevant for the
‘increased severity’ analysis. The overall global attributable
burden was only 7,000 DALYs. Even if levels of cannabis were
several times higher among people living with schizophrenia,
the extent to which we might be underestimating attributable
burden would remain very small.
It is also important to acknowledge that the improved
disability weights[36], involving surveys of the general
population, have their limitations. As discussed elsewhere[36],
it is unclear whether brief lay descriptions can accurately
capture the complexity of disability due to disorders. There is
also the possibility that considerations other than health status
may have influenced respondents’ views of “which state was
healthier” because it was hard to describe the disability due to
cannabis use without mentioning it. Nonetheless, this study has
made significant improvements in methods and in the
transparency with which burden estimates have been made.
Conclusions
Cannabis dependence causes disability across the globe. It
is a disorder primarily experienced by young adults, and our
estimates suggest that burden is higher in high income
countries. It has not been shown to increase mortality as opioid
and other forms of illicit drug dependence do. Nonetheless, in
some countries cannabis dependence produces more years
lived with disability than drugs like amphetamines and cocaine,
largely because rates of cannabis use are higher than for the
stimulant drugs. Our estimates suggest that cannabis use as a
risk factor for schizophrenia is not a major contributor to
population level disease burden.
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